



G Medical Innovations Holdings Ltd
ARBN 617 204 743

ASX Announcement

1 September 2020

ASX Confirms G Medical Delisting

Medical device, telehealth and medical services Company **G Medical Innovations Holdings Ltd (G Medical or the Company)** (ASX: GMV) refers to its announcement on 13 August 2020 in respect to its formal application for the removal of the Company from the official list of the Australian Securities Exchange (**ASX**) (**Official List**) pursuant to ASX Listing Rule 17.11 (**Delisting**) and advises that ASX has formally confirmed that it will remove the Company from the Official List subject to the conditions in the decision detailed below.

ASX'S formal decision is as follows:

Decision

Based solely on the information provided, ASX resolves to remove G Medical from the Official List of ASX pursuant to Listing Rule 17.11, on a date to be decided by ASX in consultation with G Medical, subject to compliance with the following conditions:

- (a) the Company's removal from the Official List of ASX is approved by a special resolution of shareholders of G Medical.
- (b) the notice of meeting seeking shareholder approval for G Medical's removal from the Official List must include a statement, in form and substance satisfactory to ASX, setting out:
 - (i) a timetable of key dates, including the time and date at which the Company will be removed from ASX if that approval is given;
 - (ii) details of the processes that will exist after the Company is removed from the Official List to allow a security holder to dispose of their holdings and how they can access those processes;
 - (iii) a statement to the effect that the removal will not take place any earlier than one month after security holder approval is obtained; and
 - (iv) the information, to ASX's satisfaction, prescribed in section 2.11 of ASX Guidance Note 33.
- (c) the Company releases the full terms of this decision to the market immediately.

ASX has considered Listing Rule 17.11 only and makes no statement as to the Company's compliance with other Listing Rules.

Basis for ASX Decision

Listing Rule 17.11

ASX may remove an entity from the Official List of ASX at the request of an entity. Removal from the ASX Official List at an entity's request recognises that remaining listed may no longer be suitable for a listed entity at a particular stage in its existence. There is no requirement for ASX to act on the request. ASX's power not to agree to requests for delisting enables it to ensure that delisting is not sought for inappropriate reasons or conducted in a way that is clearly harmful to the market or to security holders' legitimate interests. ASX may impose conditions on granting the request. The power to impose conditions enables ASX to ensure that an orderly market is maintained in the period leading up to the delisting, and that the listed entity makes appropriate arrangements in connection with its delisting. These may include: giving advanced notice of an amount of time which is adequate to the particular circumstances; seeking security holder approval for delisting; assisting in security holders to trade the entity's securities in another market for a period before or after delisting; or providing alternative arrangements for security holders to exit their investment before or after delisting.

Facts/Reasons for Confirmation

The Company is proposing to seek shareholder approval for its removal from the Official List of ASX, and then apply for admission and quotation on the NASDAQ exchange. G Medical will not be admitted and quoted on the NASDAQ at the time of its proposed removal, it is therefore considered that the Company's circumstances are those to which section 2.7 of Guidance Note 33 applies. Where an entity requests removal from the Official List of ASX and its ordinary securities are not readily able to be traded on another exchange at the time of its removal, ASX will usually require the entity to obtain security holder approval by way of a special resolution for removal from the Official List and that the removal does not take place any earlier

that one month after security holder approval has been obtained. An exception to these conditions are certain circumstances where the entity has been the subject of a successful takeover bid for its ordinary securities, however this exception does not apply to G Medical's case. The usual requirements will be imposed in the circumstances.

Conditions of Waiver(s)

The conditional is subject to certain conditions. Under Listing Rule 18.1, these conditions must be complied with for the confirmation to be effective.

ASX's Power to Vary or Revoke Waiver

It should be noted that under ASX Listing Rule 18.3, ASX may vary or revoke the decision at any time.

Ends

Authorised for release by Yacov Geva, Managing Director.

For more information, please contact:

Brendan De Kauwe
Director
Brendan@gmedinnovations.com

Henry Jordan
Six Degrees Investor Relations
Henry.jordan@sdir.com.au
+61 (0) 431 271 538

About G Medical Innovations:

G Medical (ASX: GMV) was founded in August 2014, aiming to be at the forefront of the digital health revolution, developing the next generation of mobile health (mHealth) technologies. The Company leverages the experience and expertise of its Board to deliver best-in-class solutions to address this global opportunity.

The Company specialises in innovative next generation mobile and telehealth solutions using its suite of proprietary devices and software solutions, as well as patient service operations, with a view to driving multiple and recurring revenue streams, across numerous verticals and territories.

For more information on G Medical, please visit www.gmedinnovations.com.

About G Medical products:

G Medical offers a suite of consumer and professional clinical-grade products (with regulatory approval) that are positioned to streamline healthcare services, improve remote access to medical data, reduce costs, improve quality of care, and make healthcare more personalized and precise. Currently the Company is focusing on two main verticals.

The 'Prizma' smartphone compatible medical device is one of two key products developed by G Medical and is aimed at everyday consumers focused on their medical health and wellbeing. The 'Prizma' allows consumers to turn their smartphone into a mobile medical monitor to measure a wide range of vital signs, with the added advantage that users are able to store their medical data in the cloud and share it with third parties such as healthcare professionals and family members.

G Medical also offers a professional real-time patient continuous monitoring solution, G Medical's Vital Signs Monitoring System (VSMS) and G Medical Patch (GMP). This modular solution measures a wide range of vital signs that are automatically presented in a call centre (IDTF) or a hospital setting. The GMP assists in diagnosing patient complaints and conditions remotely, from pre-hospitalisation, hospitalisation and through to post discharge homebased settings.